These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28089786)

  • 1. 3-Carboxyphenylboronic acid-modified carboxymethyl chitosan nanoparticles for improved tumor targeting and inhibitory.
    Wang X; Wei B; Cheng X; Wang J; Tang R
    Eur J Pharm Biopharm; 2017 Apr; 113():168-177. PubMed ID: 28089786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxorubicin delivery to 3D multicellular spheroids and tumors based on boronic acid-rich chitosan nanoparticles.
    Wang X; Zhen X; Wang J; Zhang J; Wu W; Jiang X
    Biomaterials; 2013 Jun; 34(19):4667-79. PubMed ID: 23537667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenylboronic acid-decorated gelatin nanoparticles for enhanced tumor targeting and penetration.
    Wang X; Wei B; Cheng X; Wang J; Tang R
    Nanotechnology; 2016 Sep; 27(38):385101. PubMed ID: 27514078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenylboronic Acid-Mediated Tumor Targeting of Chitosan Nanoparticles.
    Wang X; Tang H; Wang C; Zhang J; Wu W; Jiang X
    Theranostics; 2016; 6(9):1378-92. PubMed ID: 27375786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid-modified soy protein nanoparticles for enhanced targeting and inhibitory.
    Cheng X; Wang X; Cao Z; Yao W; Wang J; Tang R
    Mater Sci Eng C Mater Biol Appl; 2017 Feb; 71():298-307. PubMed ID: 27987711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chitosan/o-carboxymethyl chitosan nanoparticles for efficient and safe oral anticancer drug delivery: in vitro and in vivo evaluation.
    Feng C; Wang Z; Jiang C; Kong M; Zhou X; Li Y; Cheng X; Chen X
    Int J Pharm; 2013 Nov; 457(1):158-67. PubMed ID: 24029170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
    Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
    Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SiRNA/DOX lodeded chitosan based nanoparticles: Development, Characterization and in vitro evaluation on A549 lung cancer cell line.
    Seifi-Najmi M; Hajivalili M; Safaralizadeh R; Sadreddini S; Esmaeili S; Razavi R; Ahmadi M; Mikaeili H; Baradaran B; Shams-Asenjan K; Yousefi M
    Cell Mol Biol (Noisy-le-grand); 2016 Sep; 62(11):87-94. PubMed ID: 27755958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer.
    Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi YW; Choi HG; Park ES; Lee KC; Youn YS
    Pharm Res; 2016 Mar; 33(3):615-26. PubMed ID: 26526555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy.
    Zhu QL; Zhou Y; Guan M; Zhou XF; Yang SD; Liu Y; Chen WL; Zhang CG; Yuan ZQ; Liu C; Zhu AJ; Zhang XN
    Biomaterials; 2014 Jul; 35(22):5965-76. PubMed ID: 24768047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo study of Gal-OS self-assembled nanoparticles for liver-targeting delivery of doxorubicin.
    Guo H; Zhang D; Li T; Li C; Guo Y; Liu G; Hao L; Shen J; Qi L; Liu X; Luan J; Zhang Q
    J Pharm Sci; 2014 Mar; 103(3):987-93. PubMed ID: 24549734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and evaluation of N-caproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting.
    Lin A; Chen J; Liu Y; Deng S; Wu Z; Huang Y; Ping Q
    Drug Dev Ind Pharm; 2009 Nov; 35(11):1348-55. PubMed ID: 19832635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
    Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y
    Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery.
    Tian Q; Zhang CN; Wang XH; Wang W; Huang W; Cha RT; Wang CH; Yuan Z; Liu M; Wan HY; Tang H
    Biomaterials; 2010 Jun; 31(17):4748-56. PubMed ID: 20303163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor targeting efficiency of bare nanoparticles does not mean the efficacy of loaded anticancer drugs: importance of radionuclide imaging for optimization of highly selective tumor targeting polymeric nanoparticles with or without drug.
    Lee BS; Park K; Park S; Kim GC; Kim HJ; Lee S; Kil H; Oh SJ; Chi D; Kim K; Choi K; Kwon IC; Kim SY
    J Control Release; 2010 Oct; 147(2):253-60. PubMed ID: 20624433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromelain-decorated hybrid nanoparticles based on lactobionic acid-conjugated chitosan for in vitro anti-tumor study.
    Wei B; He L; Wang X; Yan GQ; Wang J; Tang R
    J Biomater Appl; 2017 Aug; 32(2):206-218. PubMed ID: 28618976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
    Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
    Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboxymethyl-hexanoyl Chitosan Nanodroplets for Ultrasonic Imaging and Drug Delivery to Tumor.
    Jinsui Y; Bing S; Muhua L; Yue L; Jianyi L; Meng D; Kuan C; Chaopin Y; Hui Z; Zhiyi C
    Curr Pharm Des; 2018; 24(15):1682-1688. PubMed ID: 29766795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced antitumor efficacy of arginine modified amphiphilic nanoparticles co-delivering doxorubicin and iSur-pDNA via the multiple synergistic effect.
    Song Y; Tang C; Yin C
    Biomaterials; 2018 Jan; 150():1-13. PubMed ID: 29028548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A strategy for oral chemotherapy via dual pH-sensitive polyelectrolyte complex nanoparticles to achieve gastric survivability, intestinal permeability, hemodynamic stability and intracellular activity.
    Deng L; Dong H; Dong A; Zhang J
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):107-17. PubMed ID: 26515259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.